



Quarterly Epidemiological Commentary: mandatory MRSA, MSSA, Gram-negative bacteraemias and *C. difficile* infection - October to December 2021

1 of 2

Gram-negative bacteraemias (*E. coli*, *Klebsiella* spp. and *P. aeruginosa*)

P. aeruginosa bacteraemia



October to December 2019

8

out of every

100,000 persons

developed a

P. aeruginosa bacteraemia

October to December 2021

8

out of every

100,000 persons

developed a

P. aeruginosa bacteraemia



Klebsiella spp. bacteraemia



October to December 2019

21

out of every

100,000 persons

developed a

Klebsiella spp. bacteraemia

October to December 2021

22

out of every


100,000 persons

developed a

Klebsiella spp. bacteraemia



E. coli bacteraemia



October to December 2019

75

out of every

100,000 persons

developed an

E. coli bacteraemia

October to December 2021


65

out of every

100,000 persons

developed an

E. coli bacteraemia



Quarterly Epidemiological Commentary: mandatory MRSA, MSSA, Gram-negative bacteraemias and *C. difficile* infection - October to December 2021

2 of 2

S. aureus (MRSA and MSSA) bacteraemia and *C. difficile* infections

MRSA bacteraemia



October to December 2019

1.6
out of every
100,000 persons
developed a MRSA bacteraemia

October to December 2021

1.2
out of every
100,000 persons
developed a MRSA bacteraemia



MSSA bacteraemia



October to December 2019

22
out of every
100,000 persons
developed a
MSSA bacteraemia


October to December 2021

22
out of every
100,000 persons
developed a
MSSA bacteraemia



C. difficile infection

October to December 2019



24
out of every
100,000 persons
developed a
C. difficile infection

October to December 2021

25
out of every
100,000 persons
developed a
C. difficile infection

